Abstract
Objective This study aimed to explore the association between chronic active rim+ lesions, identified as having a hyperintense rim on quantitative susceptibility mapping (QSM), on both clinical disability and imaging measures of neurodegeneration in patients with multiple sclerosis.
Methods The patient cohort was composed of 159 relapsing remitting multiple sclerosis patients aged 42.17 ± 10.25 years and disease duration of 10.74 ± 7.51 years. The Brief International Cognitive Assessment for Multiple Sclerosis and Expanded Disability Status Scale (EDSS) were used to assess clinical disability. Cortical thickness and thalamic volume were evaluated as imaging measures of neurodegeneration.
Results A total of 4,469 multiple sclerosis lesions were identified, of which 171 QSM rim+ (3.8%) lesions were identified among 57 patients (35.9%). In a multivariate regression model, as the overall total lesion burden increased, patients with at least one rim+ lesion on QSM performed worse on both physical disability and cognitive assessments, specifically the Symbol Digit Modalities Test (p=0.010), California Verbal Learning Test-II (p=0.030), and EDSS (p=0.001). In a separate univariate regression model, controlling for age (p<0.001), having at least one rim+ lesion was related to more cortical thinning (p= 0.03) in younger patients (< 45 years). Lower thalamic volume was associated with older patients (p=0.038) and larger total lesion burden (p<0.001) however, the association did not remain significant with rim+ lesions (p=0.10).
Interpretation Our findings demonstrate the significant impact of chronic active lesions, as identified on QSM, on both clinical disability and imaging measures of neurodegeneration in patients with multiple sclerosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by grants R01NS104283, 090464, 105144 and R21NS104634 from the National Institutes of Health and by grant UL1 TR000456-06 from the Weill Cornell Clinical and Translational Science Center (CTSC). Sponsors did not have a role in the study design, in the collection, analysis, interpretation of data, in the writing of the report or in the decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Weill Cornell Institutional Review Board reviewed and approved of the study design and consent forms provided to patients for this study. After ethical approval was given, informed consent was provided by every patient.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
Abbreviations
- (MS)
- multiple sclerosis
- (RR)
- relapsing remitting
- (BVMT-R)
- Brief Visuospatial Memory Test-Revised
- (CVLT-II)
- California Verbal Learning Test-II
- (EDSS)
- expanded disability status score
- (FLAIR)
- fluid attenuated inversion recovery imaging
- (QSM)
- quantitative susceptibility mapping
- (SDMT)
- Symbol Digit Modalities Test
